Prospective, randomised, multicentre, open-label study to assess the non-inferiority of a personalised precision strategy for Sudden Cardiac Death (SCD) prevention in patients with non-ischemic dilated cardiomyopathy with Left Ventricular Ejection Fraction (LVEF) ≤35%
Age ≥ 18 years at the time of screening.
Previously established diagnosis of Non-ischemic DCM
Optimised medical treatment at maximum tolerated doses for at least 3 months prior to the screening date.
NYHA functional class II-III.
History of coronary artery disease justifying the presence of ventricular dysfunction, defined as: history of coronary revascularisation or presence of significant coronary stenosis (≥50% in left main or ≥70% in a major epicardial artery) on invasive or non-invasive coronary angiography (coronary CT)
Left ventricular dysfunction attributed to congenital heart disease, valvular disease, alcohol abuse or chemotherapy.
Hypertrophic or infiltrative cardiomyopathy, active myocarditis or constrictive pericarditis.
History of recovered sudden death or sustained ventricular tachycardia.
Consorcio Centro de Investigación Biomédica en Red (CIBER)
Lead sponsor
Instituto de Salud Carlos III
Collaborator